Corvus Pharmaceuticals, Inc. (CRVS) Earnings Call Transcript & Summary

March 10, 2022

NASDAQ US Health Care Biotechnology earnings 31 min

Earnings Call Speaker Segments

Zack Kubow

executive
#1

Thanks a lot, operator, and good afternoon to all of you. We appreciate you being here for Corvus Pharmaceuticals' conference call covering our fourth quarter 2021 business update and financial results. Joining us to go over the results and business updates are Richard Miller, our Chief Executive Officer, and Leiv Lea, our Chief Financial Officer. Our executive team will kick things off with a few prepared remarks, and after that we'll take questions. I want to remind everybody that what management says today, along with responses to questions, will contain forward-looking statements. Such statements rest on estimates and assumptions as of today and carry risks and uncertainties that could lead actual results to differ materially from what those statements express or imply, including the risks and uncertainties laid out in Corvus' Annual Report on Form 10-K, filed today with the SEC, as well as other filings the company makes with the SEC from time to time. Except where the law requires it, the company assumes no obligation to publicly update or revise any forward-looking statements; with that, I'd like to hand the call over to Leiv Lea. Leiv?

Leiv Lea

executive
#2

Thanks, Zack. I'll start by giving a brief review of our financial results for the fourth quarter and the full year 2021, and after that I'll hand things over to Richard for an update on the business. As of December 31, 2021, Corvus held cash, cash equivalents and marketable securities of $69.5 million, up from $44.3 million on December 31, 2020. R&D costs for the fourth quarter of 2021 came to $4.8 million, versus $7.2 million during the comparable period of 2020. That $2.4 million decline stemmed mainly from lower clinical trial and personnel costs. For the full year 2021, R&D expenses were 21 — $29.1 million, against $31.8 million for the full year 2020. Our net loss in the fourth quarter of 2021 reached $9.2 million, whereas the same quarter of 2020 produced net income of $27.3 million. That fourth quarter 2020 net income figure reflected a non-cash net benefit of $37.2 million tied to the formation of Angel Pharmaceuticals, a company we co-founded in October 2020. If you set that item aside, the net loss would have come to $9.9 million. For the full year 2021, the net loss was $43.2 million, compared with a net loss of $6 million for the full year 2020, which likewise included the non-cash benefit from establishing Angel Pharmaceuticals. Stock compensation expense totaled $0.7 million in the fourth quarter and $4.2 million for the full year 2021, versus $1.2 million and $5.7 million in the corresponding periods of 2020. Turning ahead, we anticipate net cash used in operating activities for the full year 2022 will land somewhere between $34 million and $36 million. Now I'll pass the call to Richard.

Richard Miller

executive
#3

Thank you, Leiv, and good afternoon, everyone. Thanks for being with us today for the business update covering our fourth quarter and full year 2021. During 2021, our programs moved forward, and the laboratory and clinical findings we produced helped us spot opportunities for our product candidates that we think could point to meaningful new treatment strategies for a range of cancers. We start 2022 with three clinical programs aimed at targets of strong interest, and our intention is to take them into patients in earlier treatment settings, as well as into clinical trials at mid and later stages. Let me now go into more detail on each of our pipeline prospects and plans. As you are aware, interest in antibodies that target CD73 has risen sharply after AstraZeneca’s recent results in Stage 3 lung cancer showed that adding their anti-CD73 oleclumab to durvalumab, an anti-PDL-1 antibody, delivered a benefit. Then in February, AZ shared findings from the Neo Coast trial, a randomized Phase 2 neoadjuvant study in lung cancer that further supported the advantage of combining oleclumab with durvalumab. A number of other companies are now working on anti-CD3 agents for oncology and additional diseases. We think we have a highly differentiated antibody, and the extensive laboratory and clinical evidence behind it supports that view. We have also uncovered key biological features of the CD73 target that are allowing us to build out and broaden clinical possibilities, both in cancer and beyond. In short, the main points of differentiation for mupadolimab include these. First, it attaches to CD73 with picomolar affinity and fully shuts down adenosine production. Second, its binding to CD73 depends on concentration and reaches a plateau without any hook effect. Third, binding does not trigger internalization of the antigen, so there is no loss of antigen. Fourth, it targets a distinct epitope on the CD73 protein, something now verified by Cryo electron microscopy work, which let us resolve the molecular structure at atomic resolution. Fifth, and most significant, when it binds to B cells it activates them and drives their differentiation into plasma cells that make antibodies and into memory B cells. This characteristic does not rely on adenosine, and I want to say again that this characteristic does not rely on adenosine. Our data showing B cell activation and differentiation have been shared at conferences and published. Several recent papers from other groups are also validating how important B cells are within the tumor microenvironment. To put it simply, having B cells and plasma cells present is tied to a better prognosis and predicts response to immuno-oncology treatments. Sixth, and finally, in clinical studies that included more than 100 patients, we have worked out the safety profile, dosing, PK PD, and immunologic effects. We have reported early signals of anti-tumor activity in lung cancer and other tumor types. These data have pointed us toward a treatment strategy that pairs mupadolimab, which acts by stepping on the gas or driving immune responses, with checkpoint blockade to release the brakes on the immune system. Together, we believe these complementary approaches could make cancer immunotherapy more effective. Ongoing Phase 1b/2 studies are now evaluating this approach in patients with advanced refractory cancers of the lung and head and neck. We expect to share findings from those groups during the latter half of 2022. Building on that work, we intend to launch a randomized, blinded Phase 2 trial for the initial treatment of individuals with Stage 4 non-small cell lung cancer. Roughly 150 participants will be assigned to receive either mupadolimab combined with pembrolizumab and chemotherapy, or pembrolizumab plus chemotherapy on its own, both of which are approved standard regimens for this setting. Progression free survival will serve as the primary endpoint, while response rates and overall survival are included as secondary measures. Chemotherapy and pembro are cleared for stage four lung cancer irrespective of tumor PDL1 one expression. That means a very large share of patients with Stage 4 lung cancer can qualify for enrollment. We expect the study can begin in Q3 of 2022. Let me turn now to CPI-818, our ITK inhibitor. ITK is related to BTK and plays a role in T cell activation and expansion. As you are aware, BTK inhibitors have become widely adopted for treating B cell lymphomas. Several people on the Corvus team were instrumental in discovering and developing ibrutinib, the first BTK inhibitor. The reasoning is that CPI-818, an orally dosed small molecule, will suppress malignant T cell growth and offer benefit in T cell lymphomas, and possibly in autoimmune and allergic conditions by limiting the expansion or activation of disease-relevant T cells. At the American Society of Hematology meeting held in December 2020, we showed data from patients with peripheral T cell lymphoma, or PTCL, who received 818. Among seven individuals with very advanced refractory PTCL, we observed one complete response and one partial response. I should note that the CR lasted 19 months. Further laboratory work showed that CPI-818 produces quite striking changes in lymphocyte subsets and their functions. Our partner in China, Angel Pharmaceuticals, has licensed CPI-818 for the greater China region, and we are collaborating with them to run broader clinical studies in China as well as in the U.S and other nations. A major reason for this is that T cell lymphomas occur more frequently in Asia than in North America and Europe. Angel is currently recruiting patients into a Phase 1/1b study of CPI-818. I am pleased to say that the early antitumor signals we shared at ASH have now been confirmed in Angel’s clinical trial. I would also mention that Angel has brought on board the leading academic clinical centers in China, headed by the Beijing Cancer Center at Peking University. Going forward, Corvus and Angel will both keep enrolling patients in these Phase 1/11b trials, and our goal is to present results from those studies in the second half of this year. We are moving forward with our third clinical program, ciforadenant, in frontline renal cell cancer as part of a triplet regimen that pairs it with anti-PD-1 and anti-CTLA-4 therapies. We see a very strong scientific basis for this novel combination, one that stems from our work published in Cancer Immunology Research in 2018. To summarize, in those studies we demonstrated across several animal tumor models that ciforadenant given together with anti-CTLA-4 and anti-PD-1 was highly active, leading to a high proportion of cured animals, even when treating established tumors. Beyond the preclinical work mentioned here, we have published and presented clinical results in very advanced refractory patients with renal cell cancer showing antitumor activity for cifo both on its own and combined with anti-PD-L1 therapy. You might remember that we also found a biomarker, the Adenosine Gene Signature, that predicts who will respond to adenosine blockade. Other academic groups have since confirmed those findings. Building on our preclinical and clinical data, along with recent emerging clinical evidence that ipilimumab and nivolumab produce long-term plateaus in progression-free survival and overall survival curves, the Kidney Cancer Clinical Trial consortium and Corvus intend to run a Phase 2 trial in frontline renal cell cancer centered on the triplet of ciforadenant plus ipi and nivo.

Richard Miller

executive
#4

Roughly 60 patients are expected to be enrolled in this trial, with deep responses and progression-free survival serving as the primary endpoints. Complete responses, along with partial responses showing tumor reduction above 50%, make up what we call deep responses. By adding ciforadenant, the thinking behind this study is that we can lift the plateau on progression-free survival and survival. MD Anderson headed up the Kidney Cancer consortium, which brings in a number of prominent centers, among them Vanderbilt, Beth Israel in Boston, Cleveland Clinic, UT Southwestern and additional sites; enrollment for this study should get underway in late April of this year. Because no blinding is involved in this trial, my expectation is that we'll gain a solid early read on efficacy. To wrap up our near-term opportunities: mupadolimab is a differentiated anti-CD73 antibody, initially being developed by us for lung cancer. It's being applied within a novel immunotherapy strategy grounded in B-cell activation. Over the longer term, we see potential for broad use in additional cancers as well as infectious diseases; beyond that, we're looking into partnership possibilities that would widen the development scope for mupadolimab. CPI-818 is under investigation for T-cell lymphomas, and these studies are revealing striking impacts on T cell function, which in our view signal strong promise for other conditions such as autoimmunity and allergy. Alongside Angel, we keep treating patients in our trial across the United States, Canada, Australia, South Korea and China, aiming to launch a global Phase 2 study; and ciforadenant is now set to enter clinical evaluation in first-line renal cell cancer through a novel approach designed to boost complete remissions and deep responses. One last thing worth emphasizing. Our work with Angel and the Kidney Cancer Consortium lets us run several comprehensive clinical trials in a highly cost-efficient manner. Paired with a solid balance sheet, we possess the resources needed to advance our 3 clinical programs through a number of key milestones across the coming couple of years. At this point I'll hand the call to the operator for Q&A. Operator?

Li Watsek

analyst
#5

Hi everyone, I appreciate you answering my questions. So, I suppose the first thing — I'll go ahead. Regarding the long trial, it looks as though a Phase 2 is what you're intending to run rather than a Phase 2/3. Could you perhaps explain a bit about the reasoning behind that approach? Also, you said a Phase 2 trial got underway in, I believe, the third quarter of this year; so I'm curious about which steps are gating that. Thank you.

Richard Miller

executive
#6

All right, Li. The reason we chose a randomized blinded Phase 2 trial is that it affords us greater capability to examine the data. This isn't a registration trial. The FDA doesn't regard it as a registration trial. As a result, we can examine the data and assess efficacy as we go. That said, we won't be examining the data continuously. Within the Phase 2 trial we've incorporated interim points, at which we'll take controlled looks at how things stand from an efficacy standpoint; we have a Phase III trial set up and ready to launch. As soon as we're persuaded there's a solid efficacy signal, we start the Phase III trial, and that would be a bigger study. Essentially, this approach lets us efficiently manage the transition from Phase 2 into Phase 3, preserve capital, and still be able to examine the data. Of course, once the Phase 3 begins, we can't examine the data until that trial concludes. Then you're — pardon me, the second question concerned the ...

Li Watsek

analyst
#7

Yes ...

Richard Miller

executive
#8

So what needs to happen before we can begin? What we need is simply to have our locations arranged, secure IRB clearances, line up vendors, and so on. I'd say these are logistical matters above all, nothing beyond that.

Li Watsek

analyst
#9

All right. Thanks.

Mara Goldstein

analyst
#10

I appreciate you taking my question. I'd like to inquire specifically about the expansion cohorts for mupadolimab that were underway. At this point, where do things stand regarding getting up to those 15-patient cohorts enrolled in those particular indications? My understanding is that it involved non-small cell lung cancer along with the head and neck cancer indication, if you're willing to address that. Also, do you have any sense of when data from CPI-818 might become available to share?

Richard Miller

executive
#11

All right. Enrollment is ongoing in the expansion cohorts with mupa. Head and neck is filling up quite well. We're hoping to report some data on those later this year. Bear in mind, though, those patients differ greatly from those in our randomized Phase 2. As I noted, the randomized Phase 2 in lung is frontline. The lung and head and neck we're currently enrolling is second, third, fourth, fifth line therapy; therefore, these are extremely, extremely different patients. And in my view, that information isn't gating on our Phase 2 whatsoever, and others are observing that as well. These late-line patients are extremely, extremely different. Regarding your question about 818, let me simply state that 818 is an exciting product, we are enrolling patients, and we will present data later this year, perhaps ASH or something along those lines. In my opinion, the biology emerging from this is remarkable. I believe this is a genuinely pretty cool target.

Mara Goldstein

analyst
#12

All right. Let me just ask this — regarding that clinical program, does the global design stem from what happened at the sintilimab FDA ADCOM, or was enrolling patients outside of Asia something you expected from the start?

Richard Miller

executive
#13

No, sintilimab is completely unrelated to this. From the very beginning, our intention was to bring patients in from North America and Australia, and we completed the deal — Angel was formed so we could speed up development on a global scale. Our aim is not to run a study only with patients from China. What I'm saying is — most of the patients involved in our current efforts will come from North America.

Mara Goldstein

analyst
#14

All right. Thank you very much.

Roger Song

analyst
#15

Good. Thanks for letting us ask a couple of things. So for the first question, regarding mupa in the Phase 2 first line non-small cell lung cancer study — Rich, could you give us some detail on what assumptions went into the powering for that 150 patients? And also, you said there could potentially be several internal lots. Just to verify, from those internal lots, if an efficacy signal shows up, would you then be able to kick off a Phase 3?

Richard Miller

executive
#16

All right. Well, to begin with, this study enrolls 150 patients. The Phase 2 portion of it isn't a registration trial. So I'm not quite sure what you're getting at with power or P values. What we would be — what I'd like to do is be able to examine these data once 75 events have occurred, say somewhere between 75 and 100 events, where events mean progression. When you're dealing with a Phase 2 study of 150 patients, the way power calculations and P values work is somewhat different. My view is that a hazard ratio of 0.7 comparing the treatment arm with the control arm would be extremely good. Naturally, though, we'll also be evaluating response rate along with other measures. And bear in mind that chemo plus pembro in an all-comers lung cancer population, wild type, without excluding ALK and eGFR mutations, produces a median PFS of roughly 8 months. Incidentally, that isn't particularly impressive, and that's exactly why this trial interests us — because we believe that adding mupa — I mean, there's a solid chance, in our view, that putting a third agent into that regimen might do better. So then, Roger, in the Phase III study, that would involve — I'm not certain, perhaps 700 patients — plus an interim analysis, possibly around one-third of the way in. In that setting, you could be evaluating a hazard ratio of 0.8, which would give you 90% power to achieve P0.025. Is that clear?

Roger Song

analyst
#17

No, that sounds excellent. That provides some really helpful detail regarding those ratio thresholds. All right, so that's quite good. Then, just so I'm clear on the 818 data — you mentioned the second half of this year, possibly near ASH. Will your own Phase 1b results be part of that, along with the Angel China data, or does it come from only one of the two?

Richard Miller

executive
#18

My sense is both would be included. However, there are numerous components here. There's the clinical information, plus a great deal of quite fascinating biologic information. You need to keep in mind that nobody has ever done this previously, correct? ITK inhibition, much like when my group worked on BTK, represented truly pioneering work, and that's exactly what we're looking at here; and the only thing I can say is that this target is genuinely interesting.

Roger Song

analyst
#19

Okay, understood. Yes. So maybe past ...

Richard Miller

executive
#20

We intend to speak about this quite carefully, since investigating it turns up plenty of compelling science, numerous fresh targets, different approaches, and additional diseases. So I believe this is a topic you'll be learning more about down the road.

Roger Song

analyst
#21

Roger, you asked how the Adenosine Gene Signature biomarker is going to fit into the Kidney Clinical Trial Consortium Phase 2, or whether we have another approach to boost it.

Richard Miller

executive
#22

Richard Miller here — that's a really good question. Let me start by noting that one major academic group has already validated the Adenosine Gene Signature, and a paper from a second academic group is currently in press. So in renal cell cancer, that signature looks quite meaningful. In our frontline renal cancer study with the Kidney Cancer Consortium, we do plan to measure it, though we won't use it as a gating criterion. Nobody will be excluded because of it. If you remember, among patients whose disease is metastatic and recurrent, roughly 50% test positive for this gene signature. In the frontline setting, though, much remains to be learned. How frequently it will appear in frontline patients is unknown to me, and its predictive value might turn out differently — that's exactly why we don't want to gate on it. We need to gather that data, so we'll obtain outcomes for patients regardless of whether they are Adenosine Gene Signature positive or negative. Then we'll see.

Arthur He

analyst
#23

Good afternoon, Richard and Leiv. I'd like to ask a follow-up about the first-line lung cancer trial. For AstraZeneca, as I understand it, the COAST study involved Stage 3 lung cancer patients. If I'm remembering right, you brought up Stage 4. So could you take us through your reasoning — why Stage 4 was chosen instead of Stage 3 for this trial?

Richard Miller

executive
#24

Sure. One reason AstraZeneca went with Stage 3 lung cancer is that durvalumab, their anti-PD-L1, had approval in Stage 3 front line. That was more of a business rationale than anything else; and although they are a dominant anti-PD-1 in Stage 3, they are not the dominant antibody in Stage 4. Stage 4, incidentally, is much more common. Stage 4 disease means metastatic disease; that is considerably more common. Stage 3 means patients whose disease is locally advanced, who receive chemotherapy plus radiotherapy and then go on adjuvant durvalumab or durvalumab oleclumab; so that's a quite different clinical setting; it's somewhat earlier, but there'd be no basis to believe that the biology — that the immunobiology of lung cancer cells in Stage 3 as opposed to Stage 4 differs. We went with Stage 4 because it is much more common. We've observed some responses in metastatic disease with mupa by itself and among patients who have failed PD-1s, and we're going to put — partner our mupa alongside pembrolizumab, which is — as you know, approved — an approved agent for Stage 4 lung cancer. Those are the reasons. It isn't truly AZ's focus on Stage 3. It relates to the fact that, that's where they established their position, a couple of years back with their PACIFIC trial, okay?

Arthur He

analyst
#25

All right, understood. I appreciate the explanation. I'm just wondering about that possible registration study for mupa in first-line lung cancer. Would you consider a design that could even involve the triplet with the cifro?

Richard Miller

executive
#26

Sorry, the triplet with what included?

Arthur He

analyst
#27

Ciforadenant.

Richard Miller

executive
#28

Oh, and if you put the A2A blocker into the mix as well. What I'd say is, sure, we'd be willing to take that under consideration, though at this moment, we have — the design here is quite straightforward, for Phase 2 as well as a possible Phase 3. What you've got is pembro plus chemo, and that combination holds approval across all Stage 4 lung cancer, with the exception of the eGFR and ALK mutations, and then mupa gets layered in. But once you're looking at two experimental agents being added, things start getting somewhat more complicated.

Arthur He

analyst
#29

All right, thank you. I appreciate the extra detail.

Richard Miller

executive
#30

Very well. To start, I want to thank everyone for being on this call; we're eager to share news about what we accomplish going forward. Thanks so much.

Operator

operator
#31

Thanks. That brings today's call to a close. At this point you're free to hang up, and we appreciate everyone for joining in.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Corvus Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Corvus Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Corvus Pharmaceuticals, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.